Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:RPRX
CUSIP76028H20
Phone+1-281-7193400
Debt
Debt-to-Equity RatioN/A
Current Ratio1.18
Quick Ratio1.18
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$50,000.00
Price / Sales530.10
Cash FlowN/A
Price / CashN/A
Book Value$0.24 per share
Price / Book2.79
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-17,270,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-134.23%
Miscellaneous
Employees24
Outstanding Shares39,560,000
Market Cap$26.50 million
Repros Therapeutics (NASDAQ:RPRX) Frequently Asked Questions
What is Repros Therapeutics' stock symbol?
Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."
How were Repros Therapeutics' earnings last quarter?
Repros Therapeutics Inc (NASDAQ:RPRX) released its earnings results on Monday, November, 13th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.24. The biotechnology company earned $0.30 million during the quarter. View Repros Therapeutics' Earnings History.
What price target have analysts set for RPRX?
0 equities research analysts have issued 12 month price targets for Repros Therapeutics' stock. Their forecasts range from $0.39 to $0.39. On average, they anticipate Repros Therapeutics' share price to reach $0.39 in the next year. This suggests that the stock has a possible downside of 41.8%. View Analyst Price Targets for Repros Therapeutics.
Who are Repros Therapeutics' key executives?
Repros Therapeutics' management team includes the folowing people:
- Patrick P. Fourteau, Chairman of the Board (Age 69)
- Larry M Dillaha M.D., President, Chief Executive Officer, Director (Age 53)
- Katherine A. Anderson CPA, Chief Financial Officer, Chief Accounting Officer, Secretary (Age 58)
- Joachim F. Wernicke, Chief Medical Officer (Age 68)
- Daniel F. Cain, Independent Director (Age 70)
- Nola E. Masterson, Independent Director (Age 69)
- Saira Ramasastry, Independent Director (Age 40)
- Michael G. Wyllie Ph.D., Independent Director (Age 65)
Has Repros Therapeutics been receiving favorable news coverage?
News articles about RPRX stock have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repros Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Repros Therapeutics.
How do I buy shares of Repros Therapeutics?
Shares of RPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repros Therapeutics' stock price today?
One share of RPRX stock can currently be purchased for approximately $0.67.
How big of a company is Repros Therapeutics?
Repros Therapeutics has a market capitalization of $26.50 million and generates $50,000.00 in revenue each year. Repros Therapeutics employs 24 workers across the globe.
How can I contact Repros Therapeutics?
Repros Therapeutics' mailing address is 2408 Timberloch Pl Ste B7, THE WOODLANDS, TX 77380-1021, United States. The biotechnology company can be reached via phone at +1-281-7193400 or via email at [email protected]
MarketBeat Community Rating for Repros Therapeutics (NASDAQ RPRX)
MarketBeat's community ratings are surveys of what our community members think about Repros Therapeutics and other stocks. Vote "Outperform" if you believe RPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
